On March 8, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, reported that the company will participate in three upcoming investor conferences. Details of the company’s participation are as follows (Press release, DiaMedica, MAR 8, 2021, View Source [SID1234576334]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

33rd Annual Roth Conference
Details: DiaMedica Therapeutics management will deliver a fireside chat and participate in 1-on-1 meetings
Company conference participation date: March 15th, 2021
Oppenheimer’s 31st Annual Healthcare Conference
Details: DiaMedica Therapeutics management will deliver a corporate presentation and participate in 1-on-1 meetings
Company conference participation date: March 16th, 2021
Maxim’s Emerging Growth Conference
Details: DiaMedica Therapeutics management will deliver a corporate presentation and participate in 1-on-1 meetings
Company conference participation date: March 17th, 2021